Sarah ElShal
Papers
1
Total Citations
34
H-Index
1
About
Dr. Sarah ElShal is a leading expert at the intersection of artificial intelligence and pharmacovigilance, driving the digital transformation of drug safety monitoring. Her seminal work, "Industry Perspective on Artificial Intelligence/Machine Learning in Pharmacovigilance" (2022, 34 citations), provides a critical, multi-year analysis of how major pharmaceutical companies are integrating intelligent automation into Individual Case Safety Report (ICSR) processing. Drawing on TransCelerate member company surveys from 2019 to 2021, Dr. ElShal’s research documents a significant industry shift toward AI-powered solutions, mapping the evolution from pilot projects to broader implementation. Her contributions have established a benchmark for understanding the practical adoption of machine learning in pharmacovigilance, offering actionable insights for regulators and industry stakeholders. By systematically tracking the growing use of intelligent automation, Dr. ElShal has illuminated both the opportunities and challenges in modernizing adverse event reporting. Her work continues to shape best practices, helping to ensure that AI enhances—rather than compromises—patient safety in an increasingly data-rich regulatory landscape.
Research Focus
Key Achievements
Top Papers
- 1